Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

Abstract

BackgroundTabalumab is a human monoclonal antibody that neutralises B-cell activating factor.ObjectivesTo evaluate tabalumab efficacy and safety in patients with rheumatoid arthritis (RA).MethodsThis phase 3, randomised, double-blind, placebo-controlled study evaluated 456...